IGF-like Family Member 1 Pseudogene 2 as A Potential Drug Target Or Biomarker

Target Name: IGFL1P2

NCBI ID: G727704

IGFL1P2

Other Name(s): IGF like family member 1 pseudogene 2 | IGFL-6P

IGF-like Family Member 1 Pseudogene 2 as A Potential Drug Target Or Biomarker

IGF-like family member 1 pseudogene 2 (IGFL1P2) is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases. The IGF-like family member 1 (IGF1) pseudogene 2 gene is a member of the IGF1 gene family, which is known to encode for the insulin-like growth factor 1 (IGF1), a protein that plays a crucial role in the growth and development of tissues.

While IGF1 is widely expressed in many tissues and cells, it is also known to be involved in a number of diseases, including cancer, obesity, and neurodegenerative disorders. In addition, there is evidence to suggest that IGF1 may also be involved in the regulation of inflammation and immune responses.

One way to study the role of IGF1 in disease is to use RNA sequencing (RNA-seq) to identify differentially expressed genes in tissues or cells. This technique can reveal which genes are being expressed at different levels, and can provide insights into the functions of these genes.

One of the genes that has been identified as a potential drug target or biomarker by researchers using RNA-seq is IGFFL1P2. This gene is located on chromosome 17 and is expressed in many tissues and cells, including muscle, fat, and brain.

In addition to its expression in many tissues, IGFFL1P2 has also been shown to be involved in the regulation of insulin sensitivity and metabolism. This is important because insulin sensitivity is a key predictor of many diseases, including type 2 diabetes and cardiovascular disease.

One potential way to use IGFFL1P2 as a drug target is to target the gene directly, either by inhibiting its expression or by increasing its levels in certain tissues. This could involve using drugs that target the IGF1 signaling pathway, or by using techniques such as CRISPR/Cas9 genome editing to modify the expression of the gene.

Another approach to studying IGFFL1P2 as a potential drug target is to use it as a biomarker to predict the risk of disease. This could involve analyzing the expression of IGFFL1P2 in tissues or cells and using this information to predict which individuals are at risk for a particular disease.

While IGFFL1P2 is still in the early stages of research as a potential drug target or biomarker, there is evidence to suggest that it has the potential to be a valuable tool for the treatment of a wide range of diseases.

Protein Name: IGF Like Family Member 1 Pseudogene 2

The "IGFL1P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGFL1P2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets